Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Excess Weight Clear all
Terminated Phase 2 Interventional Results available

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

NCT02001051
View directory record Official record
Conditions
Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions
Adrenalectomy, Observation
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated No phase listed Observational

Effects of Obesity on Care and Outcomes in Mechanically Ventilated Individuals in the Intensive Care Unit

NCT00296088
View directory record Official record
Conditions
Obesity, Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

EMPOWER Clinical Trial: Vagal Blocking for Obesity Control

NCT00521079
View directory record Official record
Conditions
Obesity
Interventions
Therapy ON, Therapy OFF
Device
Lead sponsor
ReShape Lifesciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
13
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Not applicable Interventional

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

NCT03953963
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
HydraSolve T2D™
Device
Lead sponsor
Medality Medical
Industry
Eligibility
22 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity

NCT01327976
View directory record Official record
Conditions
Obesity
Interventions
vBloc (Active Device), Sham (Non-active Device)
Device
Lead sponsor
ReShape Lifesciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 9, 2026, 3:17 AM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422096
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Bottle Optimization Testing Tiny Little Eaters Study

NCT07665983
View directory record Official record
Conditions
Childhood Obesity
Interventions
Feeding
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
4 Months and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 3 Interventional

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571005
View directory record Official record
Conditions
Obesity, Overweight, Obstructive Sleep Apnoea
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
San Diego, California • Miami, Florida • Naples, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity

NCT05147909
View directory record Official record
Conditions
Physical Inactivity, Phosphate Overload, Visceral Obesity
Interventions
Sodium Phosphate, Sodium Chloride
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

NCT05558384
View directory record Official record
Conditions
Cancer, Overweight and Obesity
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 79 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

NCT05646706
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

NCT07710768
View directory record Official record
Conditions
Obesity, Overweight
Interventions
UBT251, Cocktail (Warfarin/Caffeine/Midazolam)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Interventions to Reduce Excess Weight Gain in Pregnancy

NCT01643356
View directory record Official record
Conditions
Overweight and Obesity, Pregnancy
Interventions
Intervention to reduce excess weight gain during pregnancy
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of Radiofrequency Ablation for RGB Salvage

NCT01910688
View directory record Official record
Conditions
Obesity
Interventions
RFA treatment
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Feeding Young Children Study: Bottle Weaning Intervention

NCT00756626
View directory record Official record
Conditions
Childhood Obesity
Interventions
Bottle Weaning Intervention
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Months to 13 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Not yet recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
43
States / cities
Lancaster, California • Palm Springs, California • Pomona, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Phase 3 Interventional

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Mothers-Healthy Children Nutrition

NCT03866902
View directory record Official record
Conditions
Overweight and Obesity, Adiposity, Nutrient; Excess, Physical Activity
Interventions
Nutrition and Physical Activity Intervention, English for Second Language Intervention
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
3 Years to 50 Years
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visualizing Vascular Mechanisms of Salt Sensitivity

NCT03696433
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor, Salt; Excess
Interventions
Low-salt diet, High-salt diet
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 9, 2026, 3:17 AM EDT